Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2013; 19(48): 9256-9270
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9256
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9256
Curcuminoid | Formulation | AUC (ng/mL) | Cmax (ng/mL) | tmax (h) | Relative absorption2 |
Curcumin (1a) | Curcuminphytosome high | 538.0 ± 130.7 | 50.3 ± 12.7 | 3.8 ± 0.6 | 19.21 |
Curcuminphytosome low | 272.6 ± 68.52 | 24.2 ± 5.9 | 4.2 ± 0.8 | 17.53 | |
Reference | 122.5 ± 29.3 | 9.0 ± 2.8 | 6.9 ± 2.2 | 1 | |
Demethoxycurcumin (1b) | Curcuminphytosome high | 655.0 ± 195.7 | 134.6 ± 40.6 | 2.4 ± 0.3 | 68.34 |
Curcuminphytosome low | 297.4 ± 107.3 | 39.1 ± 11.4 | 3.1 ± 0.4 | 55.54 | |
Reference | 55.8 ± 15.5 | 4.2 ± 1.1 | 4.4 ± 1.0 | 1 | |
Bisdemethoxycurcumin (1c) | Curcuminphytosome high | 142.2 ± 58.2 | 24.9 ± 8.1 | 2.2 ± 0.4 | 56.85 |
Curcuminphytosome low | 70.1 ± 34.3 | 8.8 ± 3.1 | 2.4 ± 0.6 | 53.15 | |
Reference | 24.6 ± 10.3 | 2.1 ± 0.8 | 3.4 ± 1.2 | 1 | |
Total curcuminoids | Curcuminphytosome high | 1336.0 ± 357.1 | 206.9 ± 54.9 | 2.7 ± 0.3 | 31.56 |
Curcuminphytosome low | 640.2 ± 197.7 | 68.9 ± 16.9 | 3.3 ± 0.3 | 27.26 | |
Reference | 202.8 ± 53.8 | 14.4 ± 4.2 | 6.9 ± 2.2 | 1 |
Anti-inflammatory effects | Anticancer effects |
Downregulation of NF-κB, | Inhibition of carcinogen activation |
Inhibition, via NF-κB, of COX-2, lipoxygenase, and iNOS enzymes | Stimulation of carcinogen detoxification |
Inhibition of the inflammatory cytokines, such as TNF-α, interleukin (IL)-1, -2, -6, -8, and -12, MCP, and migration inhibitory protein | Suppression of pro-inflammatory signaling |
Inhibition of PPAR-g | Inhibition of STAT |
Induction of cancer cell apoptosis cell cycle arrest | |
Inhibition of angiogenesis and metastasis | |
Modulation of oncogenes and tumor suppressor genes |
Intoxications | Pathogenetic mechanisms | Curcumin effects |
Iron (alcoholic liver disease; steatosis, viral hepatitis; anemia) | Fibrosis induced by oxidation | Anti-oxidant enzymatic activity |
Alcohol (chronic or acute intoxication) | Phospholipase A2 activation | Phospholipase A2 inhibition by NF-κB |
High-fat diet (lipid storage) | Focal degeneration, micronecrosis | Acil-CoA, cholesterol biliary acids; LDL peroxidation |
Xenobiotics induced acute damage | ROS, lipid peroxidation, inflammation | Scavenger activity on NF-κB; anti-oxidant enzymatic activity |
Xenobiotics induced chronic damage | Inflammation and hepatocellular necrosis | Hepatic fibrosis inhibition by NF-κB |
Poisons (carbon tetrachloride) | Inflammatory self-maintenance | Hepatic inflammation inhibition by NF-κB |
- Citation: Dulbecco P, Savarino V. Therapeutic potential of curcumin in digestive diseases. World J Gastroenterol 2013; 19(48): 9256-9270
- URL: https://www.wjgnet.com/1007-9327/full/v19/i48/9256.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i48.9256